Literature DB >> 25066368

Intussusception following rotavirus vaccination: an updated review of the available evidence.

Brian Rha1, Jacqueline E Tate, Eric Weintraub, Penina Haber, Catherine Yen, Manish Patel, Margaret M Cortese, Frank DeStefano, Umesh D Parashar.   

Abstract

In 1999, the first rotavirus vaccine licensed in the USA was withdrawn 9 months after introduction due to an association with intussusception that was detected in post-licensure surveillance. This association prompted large clinical trials designed to ensure the safety of two current live oral rotavirus vaccines, RotaTeq and Rotarix, which have since been recommended for use worldwide. Following their introduction, post-licensure studies have focused not only on the effectiveness and impact of these vaccines, but also on continued surveillance for intussusception. Most recent evidence from several countries shows a small increased risk of intussusception following vaccination with Rotarix and RotaTeq within the context of their demonstrated benefits. This review summarizes the available data on the safety of rotavirus vaccines with regards to intussusception.

Keywords:  intussusception; rotavirus; rotavirus disease; rotavirus vaccine; safety; vaccines

Mesh:

Substances:

Year:  2014        PMID: 25066368     DOI: 10.1586/14760584.2014.942223

Source DB:  PubMed          Journal:  Expert Rev Vaccines        ISSN: 1476-0584            Impact factor:   5.217


  12 in total

Review 1.  Vaccines against enteric infections for the developing world.

Authors:  Cecil Czerkinsky; Jan Holmgren
Journal:  Philos Trans R Soc Lond B Biol Sci       Date:  2015-06-19       Impact factor: 6.237

2.  Tandem truncated rotavirus VP8* subunit protein with T cell epitope as non-replicating parenteral vaccine is highly immunogenic.

Authors:  Xiaobo Wen; Dianjun Cao; Ronald W Jones; Yasutaka Hoshino; Lijuan Yuan
Journal:  Hum Vaccin Immunother       Date:  2015       Impact factor: 3.452

3.  Recommendations for the use of rotavirus vaccines in infants.

Authors:  Nicole Le Saux
Journal:  Paediatr Child Health       Date:  2017-06-30       Impact factor: 2.253

Review 4.  An overview of rotavirus vaccination programs in developing countries.

Authors:  Benjamin D Hallowell; Jacqueline Tate; Umesh Parashar
Journal:  Expert Rev Vaccines       Date:  2020-06-16       Impact factor: 5.683

5.  Updated cost-effectiveness and risk-benefit analysis of two infant rotavirus vaccination strategies in a high-income, low-endemic setting.

Authors:  P Bruijning-Verhagen; J A P van Dongen; J D M Verberk; R Pijnacker; R D van Gaalen; D Klinkenberg; H E de Melker; M-J J Mangen
Journal:  BMC Med       Date:  2018-09-10       Impact factor: 8.775

6.  Using surveillance and economic data to make informed decisions about rotavirus vaccine introduction.

Authors:  Adam L Cohen; Negar Aliabadi; Fatima Serhan; Jacqueline E Tate; Patrick Zuber; Umesh D Parashar
Journal:  Vaccine       Date:  2018-08-18       Impact factor: 4.169

Review 7.  A decade of experience with rotavirus vaccination in the United States - vaccine uptake, effectiveness, and impact.

Authors:  Talia Pindyck; Jacqueline E Tate; Umesh D Parashar
Journal:  Expert Rev Vaccines       Date:  2018-07-02       Impact factor: 5.683

8.  Evaluation of the Intussusception Risk after Pentavalent Rotavirus Vaccination in Finnish Infants.

Authors:  Tuija Leino; Jukka Ollgren; Nina Strömberg; Ulpu Elonsalo
Journal:  PLoS One       Date:  2016-03-07       Impact factor: 3.240

9.  Post-Marketing Benefit-Risk Assessment of Rotavirus Vaccination in Japan: A Simulation and Modelling Analysis.

Authors:  Edouard Ledent; Alfons Lieftucht; Hubert Buyse; Keiji Sugiyama; Michael Mckenna; Katsiaryna Holl
Journal:  Drug Saf       Date:  2016-03       Impact factor: 5.606

10.  Benefit Versus Risk Assessment of Rotavirus Vaccination in France: A Simulation and Modeling Analysis.

Authors:  Edouard Ledent; Hugo Arlegui; Hubert Buyse; Peter Basile; Naveen Karkada; Nicolas Praet; Gaëlle Nachbaur
Journal:  BioDrugs       Date:  2018-04       Impact factor: 5.807

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.